Abstract
According to the American Cancer Society, there will be an estimated 14,520 new cases of esophageal cancer and 174,470 new cases of lung cancer in 2005 [1]. Close to 60% of these patients with esophageal cancer will present at an advanced stage not amenable to cure, but still will require palliation of their dysphagia [2]. Conventional plastic stents (CPS) were used initially, and with continuous improvement in technology, insertion of selfexpanding metal stents (SEMS) has become the palliative treatment of choice in the majority of these patients [3-7]. SEMS are effective in palliating malignant dysphagia in 85%-100% of patients [7-9]. More recently, a new selfexpanding plastic stent (SEPS) has been designed which in early studies has been very effective in palliating dysphagia [10-13]. Similarly, the majority of patients with lung cancer will present at an advanced stage and approximately 20% of these patients will have an endobronchial component requiring some form of palliation for relief of airway obstruction [14]. Currently airway stents are either made of self-expanding metal for more permanent use, or silicone if a more temporary solution is needed. Complications similar to the esophageal stents may arise. The purpose of this article is to provide an evidence based review of stents in the palliative setting for esophageal and lung cancer and briefly explore their potential use and expanding indications in the neoadjuvant setting.
Keywords: Conventional plastic stents (CPS), selfexpanding metal stents (SEMS), Radiation, Antireflux Valves, Brachytherapy
Current Cancer Therapy Reviews
Title: A Review of the Use of Stents for Palliation of Esophageal and Lung Cancer
Volume: 3 Issue: 1
Author(s): Costas S. Bizekis, Harvey I. Pass and Michael D. Zervos
Affiliation:
Keywords: Conventional plastic stents (CPS), selfexpanding metal stents (SEMS), Radiation, Antireflux Valves, Brachytherapy
Abstract: According to the American Cancer Society, there will be an estimated 14,520 new cases of esophageal cancer and 174,470 new cases of lung cancer in 2005 [1]. Close to 60% of these patients with esophageal cancer will present at an advanced stage not amenable to cure, but still will require palliation of their dysphagia [2]. Conventional plastic stents (CPS) were used initially, and with continuous improvement in technology, insertion of selfexpanding metal stents (SEMS) has become the palliative treatment of choice in the majority of these patients [3-7]. SEMS are effective in palliating malignant dysphagia in 85%-100% of patients [7-9]. More recently, a new selfexpanding plastic stent (SEPS) has been designed which in early studies has been very effective in palliating dysphagia [10-13]. Similarly, the majority of patients with lung cancer will present at an advanced stage and approximately 20% of these patients will have an endobronchial component requiring some form of palliation for relief of airway obstruction [14]. Currently airway stents are either made of self-expanding metal for more permanent use, or silicone if a more temporary solution is needed. Complications similar to the esophageal stents may arise. The purpose of this article is to provide an evidence based review of stents in the palliative setting for esophageal and lung cancer and briefly explore their potential use and expanding indications in the neoadjuvant setting.
Export Options
About this article
Cite this article as:
Bizekis S. Costas, Pass I. Harvey and Zervos D. Michael, A Review of the Use of Stents for Palliation of Esophageal and Lung Cancer, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126584
DOI https://dx.doi.org/10.2174/157339407780126584 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploration of Structure-Based on Imidazole Core as Antibacterial Agents
Current Topics in Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Recent Advances in Developing Photosensitizers for Photodynamic Cancer Therapy
Combinatorial Chemistry & High Throughput Screening Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Current Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Antifungal Drug Discovery, Six New Molecules Patented After 10 Years of Feast:Why do we Need New Patented Drugs Apart from New Strategies?
Recent Patents on Anti-Infective Drug Discovery The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets The Photodynamic Anti-Tumor Effects of New PPa-CDs Conjugate with pH Sensitivity and Improved Biocompatibility
Anti-Cancer Agents in Medicinal Chemistry The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
Current Stem Cell Research & Therapy MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Clinical Impacts of Juxtapapillary Duodenal Diverticulum Detected on Computed Tomography
Current Medical Imaging Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology